Peer-Reviewed Published Studies

Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life
in Chronic Lung Disease 
(Rubio, 2019)

Sample†

ALL (COPD+ILD)
Number of patients sampled (n=3,471)

Sample: Patients with a diagnosis of either COPD or ILD (including emphysema, chronic bronchitis, pulmonary fibrosis, bronchiectasis, sarcoidosis, asbestosis, or unspecified interstitial lung disease).

Key Outcomes

QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status. using CCQ

Result

3-months:
73.8% improved QoL
17.4% no change/decline in QoL
91.2% total improved or did not decline

6-months:
70.5% improved QoL
18.8% no change/decline in QoL
89.3% total improved or did not decline

12-months:
61.7% improved QoL
22.8% no change/decline in QoL
84.5% total improved or did not decline

Publication Source

Rubio MM.Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease.J Clin Res Med.2019;2(4):1-8


https://centersforrespiratoryhealth.com/pdf/2019-Journal-of-Clinical-Research-and-Medicine

COPD ONLY
Number of patients sampled (n=2,813)

Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.

QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.

3-months:
75% improved QoL
16.6% no change/decline in QoL
91.6% total improved or did not decline

6-months:
72.6% improved QoL
18.3% no change/decline in QoL
90.9% total improved or did not decline

12-months:
64.1% improved QoL
22.5% no change/decline in QoL

86.6% total improved or did not decline

Rubio MM.Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease.J Clin Res Med.2019;2(4):1-8


https://centersforrespiratoryhealth.com/pdf/2019-Journal-of-Clinical-Research-and-Medicine

ILD ONLY
Number of patients sampled (n=567)

Sample: Patients with a diagnosis of interstitial lung disease (pulmonary fibrosis, sarcoidosis, asbestosis or unspecified interstitial lung disease).

QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.

3-months:
66.2% improved QoL
21.8% no change/decline in QoL
88.0% total improved or did not decline

6-months:
59.4% improved QoL
21.3% no change/decline in QoL
80.7% total improved or did not decline

12-months:
47.6% improved QoL
24.4% no change/decline in QoL
72.0% total improved or did not decline

Rubio MM.Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease.J Clin Res Med.2019;2(4):1-8

https://centersforrespiratoryhealth.com/pdf/2019-Journal-of-Clinical-Research-and-Medicine

† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation: Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.

Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy (Rubio, 2021).

Sample†

COPD ONLY
Number of patients sampled = 150

Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.

Key Outcomes

QoL measurements
at 3 months post-treatment to assess symptoms, mental health status and functional status using CCQ.

FEV1 measurements
at 3 months post-treatment.

Result

3-months:
64.0% improved QoL
20.0% had no change/decline in QoL
84.0% total improved or did not decline

3-months:
23.3% improved FEV1 by at least 15% over their baseline

3-months:
7.2% FEV1 average increase from      participants’ baseline

Publication Source

Rubio MM. Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. J Reg Med Biol Res. 2021;2(1):1-11.

https://centersforrespiratoryhealth.com/pdf/ Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.pdf

 

COPD ONLY

Number of patients sampled = 131

Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.

QoL measurements
at least 12 months post-treatment to assess symptoms, mental health status and functional status using CCQ.

FEV1 measurements
at least 12 months post-treatment

12-months:
67.2% improved QoL
8.4% had no change/decline in QoL
75.6% total improved or did not decline

12-months:
29% improved FEV1 by at least
15% over their baseline FEV1.

12-months:
6.88% FEV1 average increase from participants’ baseline

Rubio MM. Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. J Reg Med Biol Res. 2021;2(1):1-11.

https://centersforrespiratoryhealth.com/pdf/ Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.pdf

† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation: Rubio MM. Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. J Reg Med Biol Res. 2021;2(1):1-11.

Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study (Rubio, 2021).

Sample†

COPD ONLY
Number of patients sampled = 150

Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.

Key Outcomes

FEV1 measurements
at 3 months post-treatment.

Result

3-months:
67.3% improved or no decline from baseline for FEV1

3-months:
7.83% FEV1 average increase from participants’ baseline

3-months:
12.42% FEV1 average increase from Participants’ baseline (GOLD stage 4)

Publication Source

Rubio MM, et al. Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study. J Reg Med Biol   Res. 2021;2(2):1-10

https://centersforrespiratoryhealth.com/pdf/ Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study.pdf

COPD ONLY
Number of patients sampled = 419

Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.

QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.

3-months:
65.2% improved QoL
17.9% no change/decline in QoL
83.1% total improved or did not decline

6-months:
65.1% improved QoL
13.2% no change/decline in QoL
78.3% total improved or did not decline

12-months:
61.0% improved QoL
12.2% no change/decline in QoL
73.2% total improved or did not decline

Rubio MM, et al. Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study. J Reg Med Biol   Res. 2021;2(2):1-10

https://centersforrespiratoryhealth.com/pdf/ Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study.pdf

† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation:Rubio MM, et al. Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study. J Reg Med Biol   Res. 2021;2(2):1-10